Momenta Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Momenta Pharmaceuticals, Inc.
Finance Watch: LSP Dementia Fund Closes With €260m For Neurodegenerative Diseases
EQT Life Sciences completed the final close of its inaugural LSP Dementia Fund, far surpassing an initial $100m fundraising goal. Also, Resilience received a $410m commitment from the Department of Defense to fund biomanufacturing and Viking cashed in on Phase I obesity data with a $250m offering.
Seagen Deal Ticks The Big Three For Pfizer: Revenues, Pipeline, Platform
Pfizer expects Seagen’s portfolio of approved drugs and development pipeline to add $10bn in annual revenue by 2030.
Biosimilar Antibody-Drug Conjugates? Pfizer Isn’t Banking On It
Pfizer’s $43bn agreement to acquire Seagen would layer its portfolio and pipeline with vastly complex antibody-drug conjugates – a class of drug that execs feel might be almost immune to biosimilar competition. Generic firms’ history of frustration with ADCs suggests they may be right.
‘Pipeline In A Product’ Nipocalimab Starts Delivering For J&J
Johnson & Johnson splashed a lot of cash to get hold of the FcRn inhibitor and is exploring nearly a dozen indications. Nipocalimab has advanced in one of those this week, severe hemolytic disease of the fetus and newborn.
- Drug Discovery Technologies
- Other Names / Subsidiaries
- Mimeon, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.